Contraception
Volume 63, Issue 6 , Pages 289-295 , June 2001

Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20

  • Raymond Moss Hampton

      Affiliations

    • Texas Tech University School of Medicine, Lubbock, TX, USA
    • ,
  • Marilyn Short

      Affiliations

    • Johns Hopkins Medical Services, Baltimore, MD, USA
    • ,
  • Eric Bieber

      Affiliations

    • University of Chicago, Chicago, IL, USA
    • ,
  • Celine Bouchard

      Affiliations

    • Clinic Externe, Winnepeg, Canada
    • ,
  • Normand Ayotte

      Affiliations

    • Clinique de Gynecologie, Shawinigan, Canada
    • ,
  • Gary Shangold

      Affiliations

    • The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
    • ,
  • Alan C Fisher

      Affiliations

    • The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
    • ,
  • George W Creasy

      Affiliations

    • The R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-908-704-4537; fax: +1-908-704-5166

References 

  1. Hatcher RA, Guillebaud J. The pill (combined oral contraceptives). In: 17th ed..  Hatcher RA,  Trussell J,  Stewart F, et al. editor. Contraceptive technology. New York: Ardent Media, Inc; 1998;p. 405–466
  2. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception. 1989;41:399–410
  3. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies, and activities of progestogens used in contraceptives. Contraception. 1987;36:181–192
  4. Chapdelaine A, Desmarais J-L, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 1989;34:347–352
  5. Burkman RT, Kafrissen ME, Olson W, Osterman J. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand. 1992;71(Suppl 156):5–8
  6. Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials. Acta Obstet Gynecol Scand. 1990;152(Suppl):25–31
  7. Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand. 1990;152(Suppl):33–39
  8. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980. p. 9–16, 70–89.
  9. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64–72, 93.
  10. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives (risk indicators for poor pill taking and discontinuation). Contraception. 1995;51:283–288
  11. Rosenberg MJ, Burnhill MS, Waugh MS, Grimes DA, Hillard PJ. Compliance and oral contraceptives (a review). Contraception. 1995;52:137–141
  12. Summary basis of approval. NDA 19–697. Ortho Tri-Cyclen.
  13. Fraser IS. Bleeding arising from the use of exogenous steroids. Baillieres Best Pract Res Clin Obstet Gynaecol. 1999;13:203–222

PII: S0010-7824(01)00214-1

Contraception
Volume 63, Issue 6 , Pages 289-295 , June 2001

Article Tools

* Image Usage & Resolution